{"url_path":"/sec/espr/8-k/2026-06-16/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001104659-26-074558-index.html","accession_number":"0001104659-26-074558","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001104659-26-074558-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":313,"has_tables":true,"body_markdown":"false\n0001434868\n\n0001434868\n\n2026-06-15\n2026-06-15\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) \nof\nthe Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):****June 15, 2026**\n\n \n\n \n\n \n\n**Esperion\nTherapeutics, Inc.**\n\n**(Exact name of Registrant as Specified in Its\nCharter)**\n\n \n\n \n\n \n\n**Delaware**\n \n**001-35986**\n \n**26-1870780**\n\n(State\nor Other Jurisdiction of\n\nIncorporation)\n \n(Commission\n\nFile Number)\n \n(IRS\nEmployer\nIdentification No.)\n\n \n\n**3891\nRanchero Drive, Suite 150 Ann\nArbor, Michigan**\n**48108**\n\n(Address of Principal Executive Offices)\n(Zip Code)\n\n \n\n**(734****) 887-3903**\n\n**(Registrant’s Telephone Number, Including\nArea Code)**\n\n \n\n**Not Applicable**\n\n**(Former Name or Former Address, if Changed Since\nLast Report)**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing\nis intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\nx Soliciting material pursuant to\nRule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange\nAct (17 CFR 240.14d-2(b))\n\n \n\n¨ Pre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading\n\nSymbol(s)**\n \n**Name of each exchange\n\non which registered**\n\nCommon stock, par value $0.001 per share\n \nESPR\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company   ¨\n\n \n\nIf an emerging\ngrowth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with\nany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}